Research
Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage
Steven G. Morgan, Christine Leopold and Anita K. Wagner
CMAJ June 12, 2017 189 (23) E794-E799; DOI: https://doi.org/10.1503/cmaj.161481
Steven G. Morgan
School of Population and Public Health (Morgan), University of British Columbia, Vancouver, BC; Division of Health Policy and Insurance Research, Department of Population Medicine (Leopold, Wagner), Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass.
PhDChristine Leopold
School of Population and Public Health (Morgan), University of British Columbia, Vancouver, BC; Division of Health Policy and Insurance Research, Department of Population Medicine (Leopold, Wagner), Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass.
PhDAnita K. Wagner
School of Population and Public Health (Morgan), University of British Columbia, Vancouver, BC; Division of Health Policy and Insurance Research, Department of Population Medicine (Leopold, Wagner), Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass.
PharmD DrPH
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage
Steven G. Morgan, Christine Leopold, Anita K. Wagner
CMAJ Jun 2017, 189 (23) E794-E799; DOI: 10.1503/cmaj.161481
Jump to section
Related Articles
Cited By...
- The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study
- When will Canada have national pharmacare?
- Strategies to reduce out-of-pocket medication costs for Canadians with peripheral arterial disease
- Determinants of government spending on primary healthcare: a global data analysis
- Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia
- How to pay for national pharmacare
- An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011-2016): an interrupted time-series study
- Evaluating the effects of Quebecs private-public drug insurance system
- Drug prices: How do we get to a better place?